Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.017.88%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.54% | -51.60% | -32.72% | 11.33% | 10.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.54% | -51.60% | -32.72% | 11.33% | 10.67% |
| Cost of Revenue | -7.36% | 16.31% | 25.18% | 4.83% | 15.08% |
| Gross Profit | -10.24% | -61.38% | -62.23% | -1.37% | -17.23% |
| SG&A Expenses | 30.72% | 294.72% | 293.19% | 272.87% | 88.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.52% | 122.48% | 123.85% | 101.35% | 49.32% |
| Operating Income | -22.76% | -180.50% | -175.85% | -127.33% | -57.95% |
| Income Before Tax | -15.60% | -122.35% | -130.29% | -95.07% | -53.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.60% | -122.35% | -130.29% | -95.07% | -53.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 151.01% | -- | -- | -- | -- |
| Net Income | -14.76% | -119.02% | -127.10% | -93.23% | -52.57% |
| EBIT | -22.76% | -180.50% | -175.85% | -127.33% | -57.95% |
| EBITDA | -22.93% | -181.56% | -176.87% | -128.06% | -58.23% |
| EPS Basic | -15.18% | -118.06% | -127.27% | -92.42% | -51.35% |
| Normalized Basic EPS | -19.35% | -155.56% | -152.94% | -118.18% | -58.97% |
| EPS Diluted | -15.18% | -118.06% | -127.27% | -92.42% | -51.35% |
| Normalized Diluted EPS | -19.35% | -155.56% | -152.94% | -118.18% | -58.97% |
| Average Basic Shares Outstanding | 0.11% | 0.16% | 0.16% | 0.12% | 0.07% |
| Average Diluted Shares Outstanding | 0.11% | 0.16% | 0.16% | 0.12% | 0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |